This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Cancer Research UK
Sponsor:
Information provided by (Responsible Party):
Cancer Research UK
ClinicalTrials.gov Identifier:
NCT02933320
First received: September 26, 2016
Last updated: October 13, 2016
Last verified: October 2016
  Purpose
The purpose of this study is to identify the tolerable dose of BI-1206 for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody

Condition Intervention Phase
B-cell Lymphoma Chronic Lymphocytic Leukaemia Waldenström Macroglobulinaemia Biological: BI-1206 single agent dose escalation phase Biological: BI-1206 single agent expansion phase Biological: Combination of BI-1206 with Rituximab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy

Resource links provided by NLM:


Further study details as provided by Cancer Research UK:

Primary Outcome Measures:
  • Documenting Adverse Events (AEs), Serious Adverse Events (SAEs) (graded according to NCI-CTCAE Version 4.02) and laboratory parameters and determining their causality in relation to BI-1206. [ Time Frame: 53 months ]
    To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.

  • Documenting AEs, SAEs (graded according to NCI-CTCAE Version 4.02) and laboratory parameters and determining their causality in relation to BI-1206 and, where appropriate, anti-CD20 antibody. [ Time Frame: 53 months ]
    Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.


Secondary Outcome Measures:
  • Measurement of PK parameter values for BI-1206 including AUC using ELISA [ Time Frame: Samples taken during treatment and analysed in batches per cohort within 6 months of sampling ]
  • Measurement of PK parameter values for BI-1206 including Cmax using ELISA [ Time Frame: Samples taken during treatment and analysed in batches per cohort within 6 months of sampling ]
  • Measurement of PK parameter values for BI-1206 including Tmax using ELISA [ Time Frame: Samples taken during treatment and analysed in batches per cohort within 6 months of sampling ]
  • Measurement of PK parameter values for BI-1206 including half life T1/2 using ELISA [ Time Frame: Samples taken during treatment and analysed in batches per cohort within 6 months of sampling ]
  • Measurement of anti-drug antibody (ADA) response to BI-1206 during the BI-1206 treatment period using ELISA [ Time Frame: 64 months ]
    To assess immunogenicity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies

  • Measurement of peripheral blood B-lymphocyte depletion during the BI-1206 treatment period using flow cytometry. [ Time Frame: Samples taken during the first 8 weeks of treatment and reported in batches per cohort within 6 months of sampling ]
    To evaluate the effect of BI-1206 alone and in combination on the depletion of peripheral blood B-cells

  • Assessment of best disease response according to criteria for malignant lymphoma (Cheson, 2014) Waldenström macroglobulinaemia assessment criteria (Owen 2013, Kimby 2006) or NCI chronic lymphocytic leukaemia (CLL) criteria (Hallek, 2008). [ Time Frame: 64 months ]
    To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies

  • Measure progression free survival at 1 year after the first BI-1206 administration on the study for all patients [ Time Frame: 12 months ]
    To measure the time to disease progression and twelve month survival

  • Measure overall survival at 1 year after the first BI-1206 administration on the study for all patients [ Time Frame: 12 months ]
    To measure the time to disease progression and twelve month survival


Estimated Enrollment: 81
Study Start Date: October 2016
Estimated Study Completion Date: January 2022
Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A: BI-1206 single agent dose escalation phase
BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy)
Biological: BI-1206 single agent dose escalation phase
BI-1206 single agent dose escalation phase to determine the MTD or MAD and recommended Phase II dose (RP2D) for evaluation of BI-1206
Experimental: Part B: Arm 1: BI-1206 single agent expansion phase
Arm 1 will be an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A. This expansion will include a minimum of 12 chronic lymphocytic leukaemia (CLL) and six mantle cell lymphoma (MCL) patients
Biological: BI-1206 single agent expansion phase
BI-1206 single agent expansion phase at the Recommended Phase 2 Dose
Experimental: Part B: Arm 2: combination of BI-1206 with Rituximab
Arm 2 will be an investigation of combination treatment of BI-1206 with Rituximab. Arm 2 will involve an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts) and subsequent expansion of up to 25 patients at the identified recommended combination dose. This expansion will include a minimum of 12 CLL and six mantle cell MCL patients. CLL patients recruited to the expansion will receive one rituximab infusion, one week before commencing the four weeks of combination induction therapy.
Biological: Combination of BI-1206 with Rituximab
An investigation of combination treatment of BI-1206 with Rituximab.

Detailed Description:

The molecule CD32b is thought to be present on many B-cells including the malignant B-cells in some types of lymphoma and leukaemia. The study drug, BI-1206, is an anti-CD32b monoclonal antibody which attaches to CD32b on the surface of B-cells and is thought to act by recruiting host immune cells toward the tumour leading to cancer cell death as well as enhancing the anti-cancer effect of other anti-CD20 antibodies such as rituximab by stopping them being absorbed by cells.

The study is a first in man clinical trial of the drug called BI-1206 on its own and then also in combination with an anti-CD20 antibody (such as rituximab) which is commonly used to treat lymphoma and some types of leukaemia.

The four main aims of this trial are to find out:

  • The maximum dose of BI-1206 that can be given safely to patients (to a maximum dose of 800mg) on it's own and in combination with an anti-CD20 antibody, rituximab.
  • More about the potential side effects of BI-1206 and how they can be managed.
  • What happens to BI-1206 inside the body.
  • The effect of BI-1206 treatment (with or without rituximab) on tumour size and survival.

Approximately 81 patients with relapsed or refractory CD32b positive B-cell lymphoma or leukaemia will be entered into this study. This will include approximately 19 recruited for the BI-1206 dose escalation phase (Part A), up to 12 (likely 6) for a combination dose escalation and up to a further 50 patients recruited to two dose expansion cohorts; one of BI-1206 alone and one of BI-1206 plus rituximab (Part B). The final number will depend on the number of dose escalations required to reach the MTD.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.
  2. B-cell lymphoma or chronic lymphocytic leukaemia proven by histology or flow cytometry, relapsed or refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient. Patients should have received at least one line of conventional previous therapy which must have included a rituximab based regimen.
  3. CD32b positive malignancy as demonstrated centrally by immunohistochemistry or flow cytometry prior to study entry. Available tissue or blood must have been taken within six months of study entry.
  4. Life expectancy of at least 12 weeks.
  5. World Health Organisation (WHO) performance status of 0-2 (Appendix 1).
  6. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before their first dose of mAb (BI-1206 and/or rituximab) as part of this study (Day -14 to Day -7 for CLL patients recruited to the combination expansion, Day-7 to Day 1 for all other patients).

    Laboratory Test Value required

    Haemoglobin (Hb) ≥9.0 g/dL (red cell support is permissible)

    Absolute neutrophil count (ANC) ≥1.0 x 10^9/L (or >0.5 x 10^9/L if due to lymphoma), granulocyte - colony stimulating factor (G-CSF) support is not permissible at screening

    Platelet count ≥50 x 10^9/L (or ≥30 x 10^9/L if due to malignant involvement of bone marrow)

    Either:

    Serum bilirubin ≤1.5 x upper limit of normal (ULN) unless raised due to Gilbert's syndrome in which case up to 3xULN is permissible.

    Or:

    Alanine amino-transferase (ALT) and /or aspartate amino-transferase (AST) ≤ 2.5 x (ULN) unless raised due to malignant hepatic involvement in which case up to 5 x ULN is permissible

    Either:

    Calculated creatinine clearance (Cockcroft Gault) ≥30 mL/min (uncorrected value)

    Or:

    Isotope clearance measurement ≥30 mL/min (corrected)

  7. 18 years or over.
  8. B-cell lymphoma patients only: patients has at least one measurable lesion by CT scan (defined as greater than 1.5 cm in one axis) or in the case of Waldenström's macroglobulinemia, disease must be assessable by the criteria stated in Appendix 6.
  9. Patients recruited to Part B, Arm 2 (combination arm) only: CD20 positive malignancy as demonstrated by immunohistochemistry or flow cytometry prior to study entry. Analysis must have been performed within 6 months of study entry.

Exclusion Criteria:

  1. Allogenic bone marrow transplant within 12 months prior to the first dose of BI-1206 or presence of chronic graft versus host disease.
  2. Patients with clinically active leptomeningeal or central nervous system lymphoma/leukaemia.
  3. Patients with transformed lymphoma from a pre-existing indolent lymphoma. Patients with a previous history of transformation, but on this disease episode have a biopsy proven indolent recurrence may be included. Patients with proven or suspected Richter transformation are not eligible.
  4. Doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) are not permitted whilst on the study other than as pre-medication. During the screening period, doses of up to 20 mg per day may be given but the dose must be reduced to 10 mg/day by Cycle 1 Day 1 (or Day -7 in the CLL combination expansion).
  5. Known or suspected hypersensitivity to study drugs.
  6. Cardiac or renal amyloid light-chain (AL) amyloidosis.
  7. Radiotherapy, endocrine therapy, immunotherapy, chemotherapy or investigational medicinal products during the previous 4 weeks before treatment.
  8. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the Centre for Drug Development (CDD) should not exclude the patient.
  9. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two forms of contraception (one highly effective form plus a barrier method) [oral,injected or implanted hormonal contraception and condom; intra-uterine device and condom; diaphragm with spermicidal gel and condom] or agree to sexual abstinence^4 for four weeks before entering the trial, during the trial and for twelve months after completing treatment are considered eligible.
  10. Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using a barrier method of contraception [condom plus spermicide] or to sexual abstinence effective from the first administration of BI-1206 or rituximab on the study, throughout the trial and for twelve months afterwards. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence4). Men with pregnant or lactating partners should be advised to use barrier method contraception (e.g. condom plus spermicidal gel) to prevent exposure to the foetus or neonate.
  11. Major thoracic or abdominal surgery from which the patient has not yet recovered.
  12. At high medical risk because of non-malignant systemic disease including infection.
  13. Known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
  14. Patients with an active, known or suspected autoimmune disease (not including CLL auto-immune disease). Patients with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger will be permitted to participate.
  15. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior history of cardiac arrhythmia.
  16. Patients for whom rituximab is contraindicated due to severe previous hypersensitivity or any other reason (Part B combination arm only).
  17. Active, ongoing infection.
  18. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
  19. Is a participant or plans to participate in another interventional clinical study, whilst taking part in this Phase I/IIa study of BI-1206. Participation in an observational study would be acceptable.
  20. Current malignancies of other types, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for three years or more and are deemed at negligible risk for recurrence, are eligible for the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02933320

Locations
United Kingdom
Leicester Royal Infirmary Not yet recruiting
Leicester, England, United Kingdom, LE1 5WW
Contact: Contact Person       mjsd1@leicester.ac.uk   
Principal Investigator: Martin Dyer, Prof         
St Barts Hospital Not yet recruiting
London, England, United Kingdom, EC1A 7BE
Contact: Contact Person       r.l.auer@qmul.ac.uk   
Principal Investigator: Rebecca Auer, Dr         
Christie Hospital Not yet recruiting
Manchester, England, United Kingdom, M20 4BX
Contact: Contact Person       John.Radford@manchester.ac.uk   
Principal Investigator: John Radford, Prof         
Oxford Cancer and Haematology Centre, Churchill Hospital Not yet recruiting
Oxford, England, United Kingdom, OX3 7LE
Contact: Contact Person       Graham.Collins@ouh.nhs.uk   
Principal Investigator: Graham Collins, Dr         
Royal Liverpool and Broadgreen University Hospital NHS Trust Not yet recruiting
Liverpool, United Kingdom, L7 8XP
Contact: Contact Person       A.R.Pettitt@liverpool.ac.uk   
Principal Investigator: Andrew Petitt, Dr         
University Hospital Southampton NHS Foundation Trust Recruiting
Southampton, United Kingdom, S016 6YD
Contact: Contact Person       A.Davies@soton.ac.uk   
Principal Investigator: Andy Davies, Dr         
Sponsors and Collaborators
Cancer Research UK
  More Information

Responsible Party: Cancer Research UK
ClinicalTrials.gov Identifier: NCT02933320     History of Changes
Other Study ID Numbers: CRUKD16001
Study First Received: September 26, 2016
Last Updated: October 13, 2016

Keywords provided by Cancer Research UK:
Indolent B-cell Lymphoma
Chronic Lymphocytic Leukaemia
Waldenström Macroglobulinaemia
BI-1206
CD32b

Additional relevant MeSH terms:
Lymphoma
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell
Waldenstrom Macroglobulinemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Lymphoma, Non-Hodgkin
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Rituximab
Antibodies
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on August 22, 2017